Valiant Laboratories enterprise value

·Pharma & HealthChart ›
MultiplesEnterprise valuePer share
Share price at each year-end
Tap a line for its trendCurrentlast 12MFY26Mar 2026FY25Mar 2025FY24Mar 2024
683———
29.629.64.949.3
44.944.912176.1
699———
15.315.311626.7
₹128.64———
356356356313
12.6%12.6%34.1%24.3%
0.06×———
2.28×———
21.01×———
28.07×———
Reference items — trailing FY values
306237133182
33.36.4−4.7−8.4
24.90.4−6.8−10.4
—−10.41.31.9
−44.6−44.6−113−44.0
—−45.7−113−44.0
—34.211445.9
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

VALIANTLAB₹125.82

Valiant Laboratories Limited

· Pharma & Health
₹ CrorePeersALBERTDAVDHALEOSLABSZIMLABMEDICOMEDICAMEQANUHPHRAHCLWANBURYMcap ₹683 Cr
HighlightsEnterprise ValueMultiplesPer ShareAnnuals · FY-end closes
In ₹ Crore except Per Share
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Current/LTM
TTM · last close
Market Capitalization———683.4
- Cash, Equiv & ST Investments49.34.929.629.6
+ Total Debt76.1121.244.944.9
Enterprise Value———698.7
Net Debt (memo)26.7116.315.315.3
EV per Share———128.64
Total Capital312.9355.5355.8355.8
Total Debt/Total Capital24.3034.0912.6312.63
Total Debt/EV———0.06
EV/Sales———2.28
EV/EBITDA———21.01
EV/EBIT———28.07
Reference Items — Trailing FY Values
Sales182.1133.4237.5305.9
EBITDA-8.4-4.76.433.3
EBIT-10.4-6.80.424.9
Operating Cash Flow1.91.3-10.4—
Free Cash Flow-44.0-112.5-44.6-44.6
FCFF (free cash flow to the firm)-44.0-112.5-45.7—
Capital Expenditure45.9113.934.2—
Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.